Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirion Therapeutics Inc.

Division of Sirion Holdings Inc.
www.siriontherapeutics.com

Latest From Sirion Therapeutics Inc.

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

Ohr Pharma appoints new director

New York-based Ohr Pharmaceutical, which is currently developing treatments for the wet form of age-related macular degeneration and for cancer cachexia, has appointed Dr Thomas Riedhammer to its board of directors. Most recently, Dr Riedhammer was chair of Sirion Therapeutics. Prior to Sirion, he was chief operating officer at Presby, a medical device company which develops treatments for eye disorders.

Cancer Orthopedics

Alcon receives approval for acquisition of Sirion products

Alcon has received regulatory approval in the US for the acquisition of the global rights to Sirion Therapeutics' Durezol (difluprednate ophthalmic emulsion 0.05%) and the full rights excluding Latin America to Zyclorin (cyclosporine).

Infectious Diseases Orthopedics

FDA warns on unsubstantiated claims for Ista's Xibrom and Sirion's Durezol

A professional sales aid in support of Ista Pharmaceuticals' NSAID eye drop Xibrom (bromfenac ophthalmic solution) makes unsubstantiated superiority claims, broadens the indication of Xibrom, overstates its efficacy, omits and minimises important risk information, and makes misleading patient preference claims, the US FDA's division of drug marketing, advertising and communications (DDMAC) said in a warning letter to the company. It has requested a corrective messaging plan for those who received the information.

Immune Disorders Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Sirion Holdings Inc.
  • Tenby Pharma Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sirion Holdings Inc.
  • Senior Management
  • Barry Butler, Pres. & CEO
    Todd Creech, SVP, Fin. & CFO
    Philippe Boulangeat, SVP, Bus. Dev.
    Susan Benton, SVP, Sales & Mktg.
    Roger Vogel, MD, SVP, CMO
  • Contact Info
  • Sirion Therapeutics Inc.
    Phone: (813) 496-7325
    9314 E. Broadway Ave.
    Tampa, FL 33619
    USA
UsernamePublicRestriction

Register